Bancorpsouth Inc. grew its holdings in shares of GlaxoSmithKline PLC (NYSE:GSK) by 5.7% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 45,698 shares of the pharmaceutical company’s stock after buying an additional 2,467 shares during the quarter. Bancorpsouth Inc.’s holdings in GlaxoSmithKline PLC were worth $1,971,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GSK. Russell Investments Group Ltd. bought a new position in shares of GlaxoSmithKline PLC during the first quarter valued at approximately $578,000. Sei Investments Co. grew its stake in shares of GlaxoSmithKline PLC by 35.3% during the first quarter. Sei Investments Co. now owns 217,295 shares of the pharmaceutical company’s stock valued at $9,161,000 after buying an additional 56,672 shares during the last quarter. Bell Bank grew its stake in shares of GlaxoSmithKline PLC by 18.0% during the first quarter. Bell Bank now owns 52,662 shares of the pharmaceutical company’s stock valued at $2,220,000 after buying an additional 8,027 shares during the last quarter. Wedbush Securities Inc. grew its stake in shares of GlaxoSmithKline PLC by 3.3% during the first quarter. Wedbush Securities Inc. now owns 31,809 shares of the pharmaceutical company’s stock valued at $1,341,000 after buying an additional 1,026 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its stake in shares of GlaxoSmithKline PLC by 18.1% during the first quarter. Eagle Asset Management Inc. now owns 10,068 shares of the pharmaceutical company’s stock valued at $424,000 after buying an additional 1,543 shares during the last quarter. 9.28% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Bancorpsouth Inc. Has $1.97 Million Stake in GlaxoSmithKline PLC (GSK)” was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/bancorpsouth-inc-has-1-97-million-stake-in-glaxosmithkline-plc-gsk/1587252.html.

A number of research firms have recently commented on GSK. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Friday, June 16th. Citigroup Inc. cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. Zacks Investment Research cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Finally, BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and a consensus target price of $44.67.

GlaxoSmithKline PLC (NYSE:GSK) last announced its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a $0.491 dividend. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 4.84%. GlaxoSmithKline PLC’s payout ratio is presently 197.00%.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.